IPO Profile

Corcept Therapeutics
275 Middlefield Road, Suite A, Menlo Park, California 94025
Tel: 650-327-3270
Web:
Ticker: CORT
Stock Exchange: Nasdaq
Shares Issued: 4,500,000.00
Price Offered: $12.00
Amount Raised: $54,000,000.00

Underwriters:
Thomas Weisel Partners LLC
Piper Jaffray
Legg Mason Wood Walker



Company Description:
We are a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product candidate, CORLUX�, is currently in Phase III clinical trials and has been granted �fast track� status by the FDA for the treatment of the psychotic features of psychotic major depression, a disorder that affects approximately three million people in the United States each year and for which there are no FDA-approved treatments. We have also initiated a clinical proof of concept study to evaluate the tolerability and efficacy of CORLUX in improving cognition in patients with mild to moderate Alzheimer�s disease.